After a remarkable career in biopharma, Paul Edick was enjoying retirement. Then he got the call to become CEO of Xeris Pharmaceuticals.
Drawn to the organization’s technology and mission, Paul agreed to take Xeris’ helm in 2017. With Xeris, Paul has again achieved remarkable success: Since 2017, Xeris has raised over $200M in capital (including taking the company public); completed several preclinical and clinical studies; established new corporate headquarters in downtown Chicago; built a state-of-the-art lab in San Diego and grown its staff to over 100 employees.
Xeris is the latest in a long list of healthcare organizations that have achieved success under Paul's leadership. His impressive track record includes multiple biopharma startups, like Durata Therapeutics (Nasdaq: DRTX), with major acquisitions and IPOs.
Join us at the next event in our Tales from the Trenches™ series for lessons learned from Paul’s long career in biopharma and to hear about his unique journey from entrepreneurship to retirement — and back again. Jeffrey Aronin, MATTER co-founder, board member and CEO of Paragon Biosciences, will interview Paul.
5:30–6:00 | Networking
6:00–7:00 | Program (livestream available)
Tales from the Trenches is produced in partnership with Paragon Biosciences and Jumpstart Ventures.
Paul Edick is chairman and CEO of Xeris Pharmaceuticals (Nasdaq: XERS), a private technology-based company with an initial focus on therapies for diabetes-associated hypoglycemia. Prior to Xeris, Paul was founding partner of 3G Advisors, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. From 2010 to 2014, Paul served as CEO of Durata Therapeutics (Nasdaq: DRTX), a biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Durata was acquired by Actavis plc in November 2014. Prior to Durata, Paul was the CEO of Ganic Pharmaceuticals and MedPointe Healthcare.
Paul also has extensive industry experience with leading consumer, pharmaceutical and healthcare organizations including Pharmacia and Searle Pharmaceuticals, as well as leading the U.S. managed care organization, U.S. marketing organization and Global Pain & Inflammation Business, including the commercialization and launch planning for Celebrex®. In addition, Paul has also held sales, marketing, advertising and advisory positions with Procter & Gamble, Ortho Pharmaceuticals and The Hamilton Group.
Paul currently serves as the chairman of the Board of Iterum Therapeutics. Paul has also previously served on a number of pharmaceutical and healthcare company boards, including PDL BioPharma (Nasdaq: PDLI), Neos Therapeutics (Nasdaq: NEOS), NewLink Genetics Inc. (Nasdaq: NLNK), Circassia Pharmaceuticals plc (London: CIR.L), Sucampo Pharmaceuticals, (acquired by Mallinckrodt), Amerita Inc., and Informed Medical Communications. He was also chairman of the Board of Life Cycle Pharma Ltd (fka Veloxis).
About Xeris Pharmaceuticals
Xeris’ mission is to develop easier-to-use medicines that have the capacity to change lives. This year, Xeris aims to commercialize its first product, the Gvoke HypoPen™, which delivers the life-saving hormone glucagon to people with diabetes who experience a severe sudden drop in blood sugar. Learn more about Xeris.